Suppr超能文献

血小板减少症和终末期肾病是心脏植入式电子设备感染患者生存的关键预测因素。

Thrombocytopenia and end stage renal disease are key predictors of survival in patients with cardiac implantable electronic device infections.

机构信息

Department of Cardiac Surgery, Ludwig Maximilian University, Munich, Germany.

出版信息

J Cardiovasc Electrophysiol. 2020 Jan;31(1):70-79. doi: 10.1111/jce.14270. Epub 2019 Nov 20.

Abstract

INTRODUCTION

Cardiac implantable electronic device (CIED) infections are associated with a high mortality. Our aim was to identify key predictors of survival in patients with CIED infections as to be able to detect high-risk patients and possibly affect modifiable factors.

METHODS AND RESULTS

In this observational study, we collected data from 277 patients with CIED infections treated in our department between 2001 and 2017; predictors of survival were evaluated. The median time since the last CIED procedure was 0.83 years (interquartile range [IQR]: 0.25-3.01), median time since initial CIED implant was 4.79 years (IQR: 0.90-11.0 years). Survival at 30 days was 94.9% (95% confidence interval [CI]: 92.3-97.5) and survival at 1 year was 80.9% (CI: 76.4-85.7). Age (odds ratio [OR]: 1.05, CI: 1.01-1.09; P = .009), end stage renal disease (ESRD) with dialysis (OR: 5.14, CI: 1.87-14.11; P = .001), positive blood cultures (OR: 2.19, CI: 1.08-4.45; P = .030), and thrombocytopenia (OR: 2.3, CI, 1.03-5.15; P = .042) were identified as predictors of death within 1 year of treatment of CIED infection.

CONCLUSION

Patients with CIED infection with prior ESRD with dialysis or preoperative thrombocytopenia are at an increased risk of 1-year mortality. We suggest that these patients be evaluated critically and resources be allocated to these patients more liberally. A greater understanding of the role of platelets in immunity may improve treatment of advanced infection in the future.

摘要

引言

心脏植入式电子设备(CIED)感染与高死亡率相关。我们的目的是确定 CIED 感染患者生存的关键预测因素,以便能够发现高危患者,并可能影响可改变的因素。

方法和结果

在这项观察性研究中,我们收集了 2001 年至 2017 年在我们科室治疗的 277 例 CIED 感染患者的数据;评估了生存的预测因素。自最后一次 CIED 手术后的中位时间为 0.83 年(四分位距[IQR]:0.25-3.01),自首次 CIED 植入的中位时间为 4.79 年(IQR:0.90-11.0 年)。30 天生存率为 94.9%(95%置信区间[CI]:92.3-97.5),1 年生存率为 80.9%(CI:76.4-85.7)。年龄(比值比[OR]:1.05,CI:1.01-1.09;P=0.009)、终末期肾病(ESRD)伴透析(OR:5.14,CI:1.87-14.11;P=0.001)、血培养阳性(OR:2.19,CI:1.08-4.45;P=0.030)和血小板减少症(OR:2.3,CI:1.03-5.15;P=0.042)被确定为 CIED 感染治疗后 1 年内死亡的预测因素。

结论

患有 ESRD 伴透析或术前血小板减少症的 CIED 感染患者 1 年死亡率增加。我们建议对这些患者进行严格评估,并更自由地为这些患者分配资源。对血小板在免疫中的作用有更深入的了解,可能会改善未来对晚期感染的治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验